Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced.
Sign Up to like & getrecommendations! Published in 2024 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llae147
Abstract: Bimekizumab is the latest monoclonal antibody approved for the management of moderate-to-severe plaque psoriasis. Currently, data investigating its use in real-life setting are limited. Therefore, we performed a short term [(16 weeks (W)] real-life, monocentric,… read more here.
Keywords: bimekizumab; safety; bio; bio experienced ... See more keywords
OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.024
Abstract: Patients with ulcerative colitis (UC) often do not respond to treatment or lose response over time, and thus switch between therapies with various mechanisms of action (MoAs).1 Filgotinib (FIL) is a once-daily, oral, Janus kinase… read more here.
Keywords: fil 200; bio experienced; week; experienced patients ... See more keywords
P0729 Comparative clinical outcomes of advanced therapy in bio-naïve versus bio-experienced patients hospitalized with Acute Severe Ulcerative Colitis: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.0903
Abstract: The characteristics of patients with acute severe ulcerative colitis (ASUC) in East Asia differ from those in Western countries. However, the clinical outcomes of ASUC treated with advanced therapies (ATs; biologics or small molecule drugs)… read more here.
Keywords: asuc patients; clinical outcomes; bio; persistence ... See more keywords